Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bilastine monohydrate 20,776 mg - eq. bilastine 20 mg - tablet - bilastine

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - azelastine hydrochloride ophthalmic solution, 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis. azelastine hydrochloride ophthalmic solution, 0.05% is contraindicated in persons with known or suspected hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older. none. risk summary limited data from postmarketing experience over decades of use with azelastine hydrochloride in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm at oral doses approximately 5 times the clinical daily dose. oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 270 times and higher than the maximum recommended human daily intranasal dose (mrhdid) o

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinblastine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vinblastine sulfate 1 mg/ml excipient: sodium chloride sodium hydroxide sulfuric acid water for injection

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - vinblastine sulfate - solution for injection - vinblastine sulfate 1 mg/ml - antineoplastic agents

Canada - English - Health Canada

david bull laboratories (pty) ltd. - vinblastine sulfate - liquid - 1mg - vinblastine sulfate 1mg - antineoplastic agents

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - vinblastine sulfate - solution for injection/infusion - vinblastine sulfate 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

meda pharmaceuticals limited - azelastine hydrochloride; fluticasone propionate - nasal spray, suspension - azelastine hydrochloride 137 µg; fluticasone propionate 50 µg - nasal preparations

Malta - English - Medicines Authority

meda pharmaceuticals limited - azelastine hydrochloride; fluticasone propionate - nasal spray, suspension - azelastine hydrochloride 137 µg; fluticasone propionate 50 µg - nasal preparations

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 10mg (11.11 mg with 10% manufacturing overage);  ; methotrexate 10mg (11.11 mg with 10% manufacturing overage) - tablet - 10 mg - active: methotrexate 10mg (11.11 mg with 10% manufacturing overage)   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 80 starch active: methotrexate 10mg (11.11 mg with 10% manufacturing overage) excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 80 starch - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methoblastin may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced states (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.